ccl20 serum levels as a biomarker for psoriasis severity and disease-related comorbidities

Aims: psoriasis is a long-lasting inflammatory skin disease associated with immune system dysregulation and systemic complications. chemokines play a crucial role in monocyte recruitment and have been linked to the development of various autoimmune conditions. however, the relationship between chemokines and psoriasis severity, as well as their association with disease complications, remains unclear. this study aimed to propose that monitoring serum ccl20 levels in patients with psoriasis may provide valuable insights into disease severity and its associated complications.instrument & methods: this cross-sectional study was conducted on psoriasis patients. serum ccl20 levels were measured using an enzyme-linked immunosorbent assay. the psoriasis area and severity index was used to assess disease severity, and information on comorbidities was collected. statistical analyses were performed to determine associations between ccl20 levels, pasi scores, and complications.findings: the mean serum ccl20 levels in psoriasis patients were 112.14 ±8.72ng/l, with range values from 42.89 to 293.50. the mean ccl20 level was higher in mild disease (207.96±13.88) compared to 132.68±15.76 for the moderate group and 78.31±6.48 for the severe group (p=0.0001). the mean serum ccl20 levels were significantly higher in patients with metabolic syndrome (p=0.001), while the mean serum ccl20 levels were significantly lower in psoriatic patients with psoriatic arthritis compared to those without (57.63±8.05 versus 123.82±9.80, p=0.003).conclusion: there is an inverse relationship between serum ccl20 levels and the severity of psoriasis, and serum ccl20 levels are significantly associated with metabolic syndrome among psoriatic patients.